Drug intelligence / Profile preview

ABBV-181 + ABBV-368 + ABBV-927

Development stage: Unknown
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABBV-181 + ABBV-368 + ABBV-927 is an investigational three-drug combination, comprised of budigalimab (ABBV-181, an anti-PD-1 monoclonal antibody), revdofilimab (ABBV-368, an anti-TIM-3 monoclonal antibody), and giloralimab (ABBV-927, a CD40 agonist monoclonal antibody), developed by AbbVie. The combination is under study for the treatment of advanced solid tumors, including non-small-cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). Modulation of multiple immune checkpoints (PD-1, TIM-3) alongside immune co-stimulation (CD40) is designed to enhance anti-tumor immune response[1][2][4][5][9].

Other names: budigalimabrevdofilimabgiloralimab

Targets

CD40 (Cluster of differentiation 40 receptor)PDCD1 (Programmed cell death protein 1 receptor)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)

Beyond the preview

Go deeper on ABBV-181 + ABBV-368 + ABBV-927.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-181 + ABBV-368 + ABBV-927.

Explore the full profile